Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From William Looney
Strong foundational research in immunology and some promising early phase trial results have so far failed to expedite the validation of vaccines to treat cancer. In Vivo examines biopharma’s enduring optimism about the future of cancer vaccinology, including a closer look at one company’s platform to tackle the incurable malignancies that beset the mother of all organs: the human brain.
The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.
INFORMED is a new initiative at the FDA to incubate new ideas in applying big data to boost the scientific, economic and social returns from the regulation of drugs and medical devices, with a particular focus on cancer.
Pfizer, an early leader in putting patients forward in the conduct of clinical trials, is continuing to test ways to move beyond process improvements to more ambitious initiatives at the front end of technology innovation.
Roivant has a unique business model of a connected family of operationally independent companies – known as “Vants” – each with a mission to develop and commercialize new therapies for patients with unmet medical needs. In an interview with Roivant's Kris Ungvarsky, In Vivo takes a closer look at how this affect sourcing and procurement.